Eargo is intended for people who have mild to moderate hearing loss.
Eargo is intended for people who have mild to moderate hearing loss..The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers a rechargeable hearing aids that can be controlled with a smartphone. Its innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 29, 2022 | Post-IPO Equity | $29.30M | — | — | — | Detail |
Jun 27, 2022 | Post-IPO Debt | $125M | 1 | Patient Square Capital | — | Detail |
Oct 15, 2020 | IPO | $141.30M | — | — | — | Detail |
Jul 29, 2020 | Series E | $81.57M | 5 |
Gilde Healthcare
Longitude Capital |
— | Detail |
Mar 5, 2019 | Series D | $52M | 5 | Future Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Patient Square Capital | Yes | Post-IPO Debt |
Gilde Healthcare | Yes | Series E |
Longitude Capital | Yes | Series E |
Future Fund | Yes | Series D |
Charles and Helen Schwab Foundation | — | Series E |
Nan Fung Life Sciences | — | Series E |
New Enterprise Associates | — | Series E |
Maveron | — | Series D |
Schwab Institutional | — | Series D |
Charles Schwab Corporation | — | Series C |